efavirenz sandoz 600 mg, filmomhulde tabletten
sandoz b.v. veluwezoom 22 1327 ah almere - efavirenz 600 mg/stuk - filmomhulde tablet - cellulose, microkristallijn (e 460(i)) ; chinolinegeel aluminiumlak (e 104) ; croscarmellose natrium (e 468) ; hyprolose (e 463) ; hypromellose, type 2910 (3 - 15 mpa.s) (e 464) ; ijzeroxide rood (e 172) ; lactose 1-water ; macrogol 400 ; magnesiumstearaat (e 470b) ; natriumlaurilsulfaat ; titaandioxide (e 171), cellulose, microkristallijn (e 460) ; chinolinegeel aluminiumlak (e 104) ; croscarmellose natrium (e 468) ; hyprolose (e 463) ; hypromellose, type 2910 (3 - 15 mpa.s) (e 464) ; ijzeroxide rood (e 172) ; lactose 1-water ; macrogol 400 ; magnesiumstearaat (e 470b) ; natriumlaurilsulfaat (e 487) ; titaandioxide (e 171), - efavirenz
nevirapine dr. reddy's 400 mg, tablet met verlengde afgifte
dr. reddy's laboratories (uk) ltd. - nevirapine 0-water - tablet met verlengde afgifte - hypromellose (release controlling polymer)(e 464) ; hypromellose, type 2208 (release controlling polymer), k4m (e 464) ; lactose 1-water ; magnesiumstearaat (e 470b), - nevirapine
pifeltro
merck sharp & dohme b.v. - doravirine - hiv-infecties - antivirale middelen voor systemisch gebruik - pifeltro is indicated, in combination with other antiretroviral medicinal products, for the treatment of adults, and adolescents aged 12 years and older weighing at least 35 kg infected with hiv 1 without past or present evidence of resistance to the nnrti class.
efavirenz mylan 600 mg filmomh. tabl.
viatris gx bv-srl - efavirenz 600 mg - filmomhulde tablet - 600 mg - efavirenz 600 mg - efavirenz
efavirenz mylan 600 mg filmomh. tabl.
viatris gx bv-srl - efavirenz 600 mg - filmomhulde tablet - efavirenz
epclusa
gilead sciences ireland uc - sofosbuvir, velpatasvir - hepatitis c, chronisch - antivirale middelen voor systemisch gebruik - epclusa is indicated for the treatment of chronic hepatitis c virus (hcv) infection in patients 3 years of age and older (see sections 4. 2, 4. 4 en 5.
lamivudine accord 150 mg, filmomhulde tabletten
accord healthcare b.v. winthontlaan 200 3526 kv utrecht - lamivudine 0-water 150 mg/stuk - filmomhulde tablet - crospovidon (e 1202) ; hypromellose, type 2910 (3 - 15 mpa.s) (e 464) ; isomalt (e 953) ; macrogol 400 ; magnesiumstearaat (e 470b) ; polysorbaat 80 (e 433) ; titaandioxide (e 171), - lamivudine
lamivudine accord 300 mg, filmomhulde tabletten
accord healthcare b.v. winthontlaan 200 3526 kv utrecht - lamivudine 0-water 300 mg/stuk - filmomhulde tablet - crospovidon (e 1202) ; hypromellose, type 2910 (3 - 15 mpa.s) (e 464) ; isomalt (e 953) ; macrogol 400 ; magnesiumstearaat (e 470b) ; polysorbaat 80 (e 433) ; titaandioxide (e 171), - lamivudine
nevirapine sandoz retard 400 mg, tabletten met verlengde afgifte
sandoz b.v. veluwezoom 22 1327 ah almere - nevirapine 0-water 400 mg/stuk - tablet met verlengde afgifte - cellulose, microkristallijn (e 460(i)) ; magnesiumstearaat (e 470b) ; polyethyleenoxide ; povidon k 25 (e 1201) ; siliciumdioxide (e 551), cellulose, microkristallijn (e 460) ; magnesiumstearaat (e 470b) ; polyethyleenoxide ; povidon k 25 (e 1201) ; siliciumdioxide (e 551), - nevirapine
adempas
bayer ag - riociguat - hypertensie, pulmonair - antihypertensiva voor pulmonale arteriële hypertensie - chronic thromboembolic pulmonary hypertension (cteph)adempas is indicated for the treatment of adult patients with who functional class (fc) ii to iii withinoperable cteph,persistent or recurrent cteph after surgical treatment,to improve exercise capacity. pulmonary arterial hypertension (pah)adultsadempas, as monotherapy or in combination with endothelin receptor antagonists, is indicated for the treatment of adult patients with pulmonary arterial hypertension (pah) with who functional class (fc) ii to iii to improve exercise capacity. de werkzaamheid is aangetoond in een pak van de bevolking inclusief de oorzaken van idiopathische of erfelijke pah of pah geassocieerd met bindweefselaandoeningen. paediatricsadempas is indicated for the treatment of pah in paediatric patients aged less than 18 years of age and body weight ≥ 50 kg with who functional class (fc) ii to iii in combination with endothelin receptor antagonists.